Below is copied a press release issued jointly by two all party parliamentary groups (drug misuse and primary care and public health) this week calling for the MRHA not to reclassify over the counter medicines containing ephedrine and pseudo ephedrine as prescription only.
This follows on from the recent kerfuffle about the dangers of cold remedies, such as Lemsip and Sudafed which contain the drugs in question (albeit in relatively tiny doses), being used in the illicit manufacture of meth amphetamine. As discussed here the recent War on Lemsip blog such a move would be largely gesture politics, and have no discernible impact on the production supply and use of meth amphetamine. As we have seen over the past century's experience of trying to prohibit drugs that are in demand, such moves will always fail. If there is profit to be made then illicit markets will always find a way to produce and supply.
Curiously though, in the UK at least there is no such demand. Methamphetamine use is relatively insignificant, with demand for stimulants being more than met with the more familiar amphetamine market (as well as other stimulants like cocaine and crack). Indeed the difference from a public health perspective between amphetamine and meth amphetamine is very little. Meth may be more potent and longer acting but of course there is nothing to stop the amphetamine user taking bigger doses more often. If banning lemsip etc is supposed to nip the problem in the bud then policy makers in the Home Office and MHRA are deluding themselves. Such moves have been tried in the US and shown to be completely ineffective. Similarly making the drug Class A as happened recently in the UK will be entirely ineffective as discussed on the blog here.
There is a danger here that we are buying into a classic drug panic. It is interesting to note that the language and discourse of the nascent meth panic is almost identical to previous drug panics, indeed apart from the drug name itself the latest accounts of misery, addiction, depravity and death associated with meth are virtually indistinguishable from those in the 90s associated with crack, the 70's and 80's with cocaine and PCP. Going back further still they are not that different from cannabis in the 30's and even alcohol in the 20's.
The parliamentarians are to be applauded for having the pragmatism not to throw the baby out with the bath water, and prevent legitimate access to everyday medicines because of a largely politically driven panic about an as yet non-existent problem.
Meth: coming soon to a drug den near you (maybe)
ALL PARTY PARLIAMENTARY GROUPS
Primary Care and Public Health
Joint inquiry: Proposals to restrict the availability of medicines containing ephedrine and pseudoephedrine
Parliamentarians don’t support Reclassification of Pseudoephedrine
The Joint Inquiry Report into proposals to restrict the availability of medicines containing pseudoephedrine and ephedrine by the All Party Parliamentary Group on Primary Care & Public Health and the executive members of the All Party Parliamentary Drugs Misuse Group has been submitted to the MHRA in response to their consultation MLX 337. It has also been sent to Health Ministers and the Home Office.
The inquiry, which also held an urgent oral session on 18th April 2007, received evidence from multi-stakeholder organisations including patient and consumer groups, Drugscope (the drug charity), law enforcement agencies, MHRA, medical bodies and industry. Organisations that supported the MHRA proposal to reclassify medicines to POM were the BMA, Nursing & Midwifery Council, ACPO and of course the MHRA, the majority of evidence received however were opposed to the reverse switch.
In the Inquiry Report, the two Groups concluded that the evidence received by the law enforcement agencies and MHRA was not sufficient to justify the reclassification of medicines containing ephedrine and pseudoephedrine to prescription only. This is especially the case, according to the Groups, because the controls that are currently in place in the UK are similar to those that exist in countries where there is an acknowledged methylamphetamine problem.
The Groups recommended a mixture of statutory and non-statutory controls:
- reduce OTC medicine pack sizes to contain a maximum of 720mg through statute
- limit the sales of products to one pack per person
- tighten the pharmacy control of these medicines by working with the pharmacy profession to strengthen their vigilance in sale and supply
- ensure the monitoring of the situation on a regular basis by a stakeholder group including law enforcement agencies, MHRA, pharmacy and industry, enabling a quick response should the situation change to a high risk of harm.
For further details please contact Libby Whittaker who provides the secretariat for the All Party Parliamentary Group on Primary Care & Public Health on 020 7421 9318 or email email@example.com